The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM
暂无分享,去创建一个
L. Schwartz | R. Figlin | S. Hancock | R. Motzer | E. Jonasch | T. Choueiri | N. Agarwal | M. Fishman | M. Michaelson | T. Olencki | B. Redman | P. Lange | M. Carducci | T. Kuzel | J. Sheinfeld | A. Kessinger | G. Hudes | C. Beard | C. Robertson | R. Pili | K. Margolin | G. Bolger | B. Boston | E. Levine | Jue Wang
[1] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[2] R. Figlin,et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) , 2008 .
[3] Bohuslav Melichar,et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.
[4] J. Elting,et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis , 2007 .
[5] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[6] L. Chow,et al. Sunitinib: from rational design to clinical efficacy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Bukowski,et al. Randomized phase III trial of sorafenib in advanced renal cell carcinoma (RCC): Impact of crossover on survival. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Staehler. Sorafenib in Advanced Renal Cancer , 2007, Drugs.
[9] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[10] P. Russo. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma , 2006 .
[11] David C. Miller,et al. Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. , 2006, Urology.
[12] O. Rouvière,et al. Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? , 2006, Nature Clinical Practice Oncology.
[13] A. Oza,et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] Jeffrey W. Clark,et al. Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors , 2005, Clinical Cancer Research.
[15] C. Tangen,et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. , 2005, The Journal of urology.
[16] M. Piccart,et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours , 2005, British Journal of Cancer.
[17] F. Marshall. Phase II Clinical Trial of Interactive MR Imaging-Guided Interstitial Radiofrequency Thermal Ablation of Primary Kidney Tumors: Initial Experience , 2005 .
[18] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Milowsky,et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma , 2004, Cancer.
[20] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[21] D. Gervais,et al. Radiofrequency ablation: an alternative treatment method of renal cell carcinoma. , 2004, Chang Gung medical journal.
[22] E. Small,et al. A phase II study of gemcitabine (G) and capecitabine (C) in patients with metastatic renal cell cancer (mRCC): A report of Cancer and Leukemia Group B #90008. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Cheville,et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. , 2004, The Journal of urology.
[24] R. Figlin,et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] S. Steinberg,et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Seth M Steinberg,et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.
[27] J. Manola,et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] V. Sukhatme,et al. Renal cancer: molecular mechanisms and newer therapeutic options , 2002, Current opinion in nephrology and hypertension.
[29] N. Munshi,et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.
[30] R. Sylvester,et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.
[31] J. Buer,et al. Capecitabine in the treatment of metastatic renal cell carcinoma , 2000, British Journal of Cancer.
[32] M. Burt,et al. Resection of metastatic renal cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Ravaud,et al. Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma , 1998 .
[34] R. Fisher,et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. , 1997, The cancer journal from Scientific American.
[35] H. Hricak,et al. Magnetic resonance imaging in the diagnosis and staging of renal and perirenal neoplasms. , 1985, Radiology.
[36] W. Gunn. Cancer: Principles and Practice of Oncology , 1982 .
[37] S. Fosså,et al. Radiotherapy of metastases from renal cancer. , 1982, European urology.
[38] M. Gordon. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 , 2009 .
[39] M. Gordon,et al. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma , 2008 .
[40] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] J. Lam,et al. Open partial nephrectomy for the treatment of renal cell carcinoma , 2006, Current urology reports.
[42] B. Konety. Renal cryoablation: Outcome at 3 years , 2006 .
[43] M. Blute,et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. , 2003, The Journal of urology.
[44] P. Choyke,et al. Hereditary renal cancers. , 2003, Radiology.
[45] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] G. Kramer,et al. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[47] D. Mendelson,et al. Comparison of MRI and CT for study of renal and perirenal masses. , 1991, Critical reviews in diagnostic imaging.